Popular children's cough medicine recalled over potentially deadly bacterial infection risk
A popular cough medicine for children has been recalled over a risk of bacterial infection that can be deadly.
Little Remedies Honey Cough Syrup was recalled Tuesday over the 'presence' of Bacillus cereus, a type of bacteria that can cause two types of foodborne illnesses, and because of 'loss of shelf-stability,' according to a notice from the medicine makers, Medtech Products Inc.
The recall describes the symptoms associated with both foodborne illnesses. One can cause nausea, vomiting and stomach cramps starting one to six hours after consuming contaminated food. The second illness can cause stomach cramps and diarrhea starting 8 to 16 hours after exposure.
'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death,' the recall notice warned.
No serious adverse effects have been reported as of the date of the recall.
The recalled cough syrup was sold by retailers throughout the country and online from December 14, 2022, to June 4, 2025.
Consumers with the recalled medicine are advised to stop using it immediately and contact their doctor if they experience any symptoms that may be related to the product. The company is also offering a refund of the product.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
41 minutes ago
- Telegraph
This firm represents one of investing's toughest moral debates
While many big drug companies do amazing things for humanity, they're also often vilified for profiteering from their work. This month, New York-listed Gilead Sciences has, not for the first time, reminded investors of the conundrum. On June 18, Gilead announced it had gained approval from the US regulator for a treatment that some view as having the potential to end the global 'HIV epidemic'. At the same time, it has drawn criticism in anticipation of US prices being set at more than $28,000 (£20,400) per patient, per year. Lenacapavir, to be marketed by Gilead under the name Yeztugo, is a twice-yearly injection that prevents people from contracting HIV. This has the potential to disrupt the market for preventative HIV drugs, which is currently dominated by another Gilead treatment, a daily pill named Descovy. Financially, Gilead hopes to gain from lenacapavir by expanding the market for preventative HIV treatments. It also could benefit from existing users of Descovy switching to the somewhat more expensive new treatment, and people switching from other long-lasting preventatives such as GSK's bi-monthly Apretude. The breakthrough is important in strengthening Gilead's HIV franchise more broadly, too. HIV drugs accounted for almost 70pc of product sales last year, and year-on-year growth of HIV-related revenues came in at 8pc in the first quarter. The group's single biggest-selling drug is Biktarvy, a treatment for people who are already HIV positive. The daily oral pill generates around $13.4bn of sales, or 47pc of the group total. Gilead is currently leveraging its research into lenacapavir by attempting to develop a twice-yearly treatment in this space, too. Gilead's major drug breakthroughs have not always proved as rewarding for shareholders as they have for patients. Covid-19 sent the shares on a roller-coaster ride after one of Gilead's hepatitis C treatments, called Remdesivir, was originally found to also be very effective against the coronavirus. Sales of the drug, rebranded Veklury, hit $5.6bn in 2021 but rapidly fell as the pandemic eased, and revenues are expected to be just $1.3bn this year. An earlier breakthrough in the treatment of hepatitis C in the 2010s, meanwhile, caused huge share price excitement, with revenues ballooning to nearly $14bn in 2015 before the drug became a victim of its own success. Because the drug, called Harvoni, found a way to cure the disease as opposed to managing it, it did away with much of its own market. Rising competition also contributed to a rapid decline in sales. However, many top investors are more bullish on the lenacapavir breakthrough. Financial publisher Citywire, which tracks where the world's best fund managers are investing, has found 12 backing the shares – all among the best-performing 3pc of equity managers globally. The level of these bets puts Gilead among the 74 stocks that make up Citywire's Global Elite Companies index, which represents the very best ideas from the roughly 6,000 stocks held across the portfolios of top fund managers. Optimism about Gilead's prospects can be seen in its share price, too. The valuation against forecast earnings is within the top 5pc of the 10-year range. While in some circumstances this would be grounds to worry about the shares being expensive, the fact Gilead is only valued at 13 times forecast earnings makes it is more a reason to take heart than worry. Indeed, the uninspiring valuations of previous years reflect the ups and downs associated with Veklury and Harvoni. Today, the future looks much brighter. Sales of Veklury appear to be stabilising and now represent a relatively small proportion of the business. Meanwhile, as well as the strong HIV franchise, the company is experiencing solid growth in cancer and liver disease treatments. The drug development pipeline also looks strong, and is supported by about a fifth of sales going into research and development (R&D) each year. The group also does not face any major loss of patents until 2033. Meanwhile, attempts to drive down operating costs are benefiting the bottom line. The good progress has been reflected in analysts raising their earnings forecasts over the last 12 months. Expectations for the current year and next are both up by more than 10pc over the period, and while there is some downward pressure on revenue from US drug pricing policies, Gilead looks relatively well placed due to its focus on novel medicines. Its extensive US operations also reduce the threat from tariffs. The shares offer an attractive 3pc forecast dividend yield, and the company has a strong track record for returning cash. British buyers of the shares, which are available through all the big broking platforms, need to fill out the current paperwork to minimise withholding tax and should also check for any extra dealing charges. While walking the tightrope between profit and purpose is never easy, as an investment, Gilead looks better placed than it has for quite some time. Questor says buy Ticker: NYSE:GILD
Daily Mail
an hour ago
- Daily Mail
EXCLUSIVE I died and came back after being shown the true meaning of life... everything you've been taught is wrong
A lawyer and devout Catholic grew up believing life and death were black and white until an extraordinary experience changed her entire view of the universe. During a near-death experience, Nanci Danison of Ohio said she received an astonishing revelation that everything in existence is part of an energy source that incarnates inside humans as what we call souls.
Daily Mail
2 hours ago
- Daily Mail
Joe Rogan reveals his huge fears about bread in America
Joe Rogan has voiced fears about the ingredients used in bread in America, warning that it 'makes a difference' when it is cut from a diet. The popular podcaster was speaking with comedian Jim Norton when he aired concerns about Americans often feel lethargic and unwell after eating bread, but Europeans can consume high qualities without issues. Norton said: 'Our bread is f***ed. Our bread is so f***ed. Go overseas to Italy and eat bread. You don't feel bad at all. Our s**t is poison.' Rogan agreed, adding: 'It won't matter if it's World War 3, but if it's not World War 3, probably stay away from bread.' He issued a caveat for sourdough bread specifically, telling his listeners to 'eat sourdough bread... [it] is great for you.' Rogan then referred to a video he'd seen on social media, sent to him by stand up comedian Brian Simpson. 'Simpson sent me this and he said ''I think I'm done with bread'' and I was like... oh my God this is kind of crazy.' In the video, a creator explains the differences between bread commonly served in America versus the rest of the world. 'What we call bread can't even be considered food in parts of Europe. See, here in America, it's not so much the gluten as what we've done to the grain,' the creator, later identified by Rogan as Dennis Echelbarger, said. 'About 200 years ago, we started stripping the bran and germ or the fiber in nutrients to make flour shelf stable, also nutritionally dead,' he said. 'Because the nutrients were gone, we enriched it with folic acid, which a large majority of the population can't even metabolize therefore many people experience fatigue, anxiety, hyperactivity and inflammation. But then the bread wasn't white enough, so they bleached it with chlorine gas. 'The bread didn't rise enough, so they added a carcinogen called potassium bromate, which is banned in several countries like Europe, the UK and even China. Then we wanted to ramp up production, so we started using glyphosate to dry out the wheat before harvest, causing endocrine disruption and damaging your gut. 'So now you're bloated, brain fogged, tired and blamed gluten. But gluten is just the scapegoat.' Instead, the video states 'the real issue is ultra processed, chemically altered, bleached, bromated, fake vitamin filled wheat soaked in glyphosate. This isn't bread.' Rogan said the video should be mandatory viewing 'for everybody to see.' 'I know when I cut that stuff out of my diet it makes a difference,' he said. 'Most of the bread you're getting in America is like that guy described and that's why you feel like s**t when you eat it.' Rogan's short video was inundated with Americans who had moved overseas and could vouch for his message. 'As someone who recently moved to Italy, I truly now have a better appreciation for bread than I ever did,' one wrote. 'Lived in Germany and the bread there is next level. Now I live Japan and the bread is also way better than the US but not better than EU,' another added.
